Genetic and functional characterization of putative Ras/Raf interaction inhibitors in C. elegans and mammalian cells

Journal of Molecular Signaling

Volumn 5, Issue , 2010, Pages

  González Pérez, Vanessa ^a   Reiner, David J ^a,b   Alan, Jamie K ^b   Mitchell, Cicely ^c   Edwards, Lloyd J ^c   Khazak, Vladimir ^d   Der, Channing J ^a,b   Cox, Adrienne D ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c IL   (United States)

^d NexusPharma Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAENORHABDITIS ELEGANS; MAMMALIA;

EID: 77649325767     PISSN: None     EISSN: 17502187     Source Type: Journal    
DOI: 10.1186/1750-2187-5-2     Document Type: Article

References (59)

1. Campbell PM, Der CJ. Oncogenic Ras and its role in tumor cell invasion and metastasis. Semin Cancer Biol 2004, 14:105-114. 10.1016/j.semcancer.2003.09.015, 15018894.
2. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989, 49:4682-4689.
3. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954. 10.1038/nature00766, 12068308.
4. Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004, 6:313-319. 10.1016/j.ccr.2004.09.022, 15488754.
5. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009, 9:537-549. 10.1038/nrc2694, 19629069.
6. Khazak V, Astsaturov I, Serebriiskii IG, Golemis EA. Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets 2007, 11:1587-1609. 10.1517/14728222.11.12.1587, 2720036, 18020980.
7. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004, 4:937-947. 10.1038/nrc1503, 15573115.
8. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26:3291-3310. 10.1038/sj.onc.1210422, 17496923.
9. Cox AD, Der CJ. Ras family signaling: therapeutic targeting. Cancer Biol Ther 2002, 1:599-606.
10. Blum R, Cox AD, Kloog Y. Inhibitors of chronically active ras: potential for treatment of human malignancies. Recent Pat Anticancer Drug Discov 2008, 3:31-47. 10.2174/157489208783478702, 18289122.
11. Lyons JF, Wilhelm S, Hibner B, Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001, 8:219-225. 10.1677/erc.0.0080219, 11566613.
12. Lee JT, McCubrey JA. BAY-43-9006 Bayer/Onyx. Curr Opin Investig Drugs 2003, 4:757-763.
13. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109. 10.1158/0008-5472.CAN-04-1443, 15466206.
14. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006, 5:835-844. 10.1038/nrd2130, 17016424.
15. Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE, Gambacorti-Passerini C. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res 2008, 6:751-759. 10.1158/1541-7786.MCR-07-2001, 18458053.
16. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008, 105:3041-3046. 10.1073/pnas.0711741105, 2268581, 18287029.
17. Friday BB, Adjei AA. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 2008, 14:342-346. 10.1158/1078-0432.CCR-07-4790, 18223206.
18. Khazak V, Golemis EA, Weber L. Development of a yeast two-hybrid screen for selection of human Ras-Raf protein interaction inhibitors. Methods Mol Biol 2005, 310:253-271. full_text, 16353379.
19. Lu Y, Sakamuri S, Chen QZ, Keng YF, Khazak V, Illgen K, Schabbert S, Weber L, Menon SR. Solution phase parallel synthesis and evaluation of MAPK inhibitory activities of close structural analogues of a Ras pathway modulator. Bioorg Med Chem Lett 2004, 14:3957-3962. 10.1016/j.bmcl.2004.05.048, 15225706.
20. Kato-Stankiewicz J, Hakimi I, Zhi G, Zhang J, Serebriiskii I, Guo L, Edamatsu H, Koide H, Menon S, Eckl R, et al. Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. Proc Natl Acad Sci USA 2002, 99:14398-14403. 10.1073/pnas.222222699, 137895, 12391290.
21. Campbell PM, Groehler AL, Lee KM, Ouellette MM, Khazak V, Der CJ. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res 2007, 67:2098-2106. 10.1158/0008-5472.CAN-06-3752, 17332339.
22. Skobeleva N, Menon S, Weber L, Golemis EA, Khazak V. In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway- and microtubule-targeting inhibitors. Mol Cancer Ther 2007, 6:898-906. 10.1158/1535-7163.MCT-06-0602, 2670615, 17363484.
23. Hao H, Muniz-Medina VM, Mehta H, Thomas NE, Khazak V, Der CJ, Shields JM. Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth. Mol Cancer Ther 2007, 6:2220-2229. 10.1158/1535-7163.MCT-06-0728, 17699719.
24. Lackner MR, Kindt RM, Carroll PM, Brown K, Cancilla MR, Chen C, de Silva H, Franke Y, Guan B, Heuer T, et al. Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors. Cancer Cell 2005, 7:325-336. 10.1016/j.ccr.2005.03.024, 15837622.
25. Reiner DJ, Gonzalez-Perez V, Der CJ, Cox AD. Use of Caenorhabditis elegans to evaluate inhibitors of Ras function in vivo. Methods Enzymol 2008, 439:425-449. full_text, 18374181.
26. Moghal N, Sternberg PW. The epidermal growth factor system in Caenorhabditis elegans. Exp Cell Res 2003, 284:150-159. 10.1016/S0014-4827(02)00097-6, 12648474.
27. Beitel GJ, Clark SG, Horvitz HR. Caenorhabditis elegans ras gene let-60 acts as a switch in the pathway of vulval induction. Nature 1990, 348:503-509. 10.1038/348503a0, 2123303.
28. Chong H, Lee J, Guan KL. Positive and negative regulation of Raf kinase activity and function by phosphorylation. EMBO J 2001, 20:3716-3727. 10.1093/emboj/20.14.3716, 125532, 11447113.
29. Lackner MR, Kim SK. Genetic analysis of the Caenorhabditis elegans MAP kinase gene mpk-1. Genetics 1998, 150:103-117. 1460334, 9725833.
30. Beitel GJ, Tuck S, Greenwald I, Horvitz HR. The Caenorhabditis elegans gene lin-1 encodes an ETS-domain protein and defines a branch of the vulval induction pathway. Genes Dev 1995, 9:3149-3162. 10.1101/gad.9.24.3149, 8543158.
31. Hara M, Han M. Ras farnesyltransferase inhibitors suppress the phenotype resulting from an activated ras mutation in Caenorhabditis elegans. Proc Natl Acad Sci USA 1995, 92:3333-3337. 10.1073/pnas.92.8.3333, 42160, 7536929.
32. Rocheleau CE, Ronnlund A, Tuck S, Sundaram MV. Caenorhabditis elegans CNK-1 promotes Raf activation but is not essential for Ras/Raf signaling. Proc Natl Acad Sci USA 2005, 102:11757-11762. 10.1073/pnas.0500937102, 1187957, 16085714.
33. Yoder JH, Chong H, Guan KL, Han M. Modulation of KSR activity in Caenorhabditis elegans by Zn ions, PAR-1 kinase and PP2A phosphatase. EMBO J 2004, 23:111-119. 10.1038/sj.emboj.7600025, 1271663, 14685271.
34. de Rooij J, Bos JL. Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras. Oncogene 1997, 14:623-625. 10.1038/sj.onc.1201005, 9053862.
35. Taylor SJ, Shalloway D. Cell cycle-dependent activation of Ras. Curr Biol 1996, 6:1621-1627. 10.1016/S0960-9822(02)70785-9, 8994826.
36. Bivona TG, Quatela S, Philips MR. Analysis of Ras activation in living cells with GFP-RBD. Methods Enzymol 2006, 407:128-143. 10.1016/S0076-6879(05)07012-6, 16757320.
37. Chiu VK, Bivona T, Hach A, Sajous JB, Silletti J, Wiener H, Johnson RL, Cox AD, Philips MR. Ras signalling on the endoplasmic reticulum and the Golgi. Nat Cell Biol 2002, 4:343-350.
38. Chong H, Guan KL. Regulation of Raf through phosphorylation and N terminus-C terminus interaction. J Biol Chem 2003, 278:36269-36276. 10.1074/jbc.M212803200, 12865432.
39. Harding A, Hsu V, Kornfeld K, Hancock JF. Identification of residues and domains of Raf important for function in vivo and in vitro. J Biol Chem 2003, 278:45519-45527. 10.1074/jbc.M303106200, 12954633.
40. Han M, Sternberg PW. let-60, a gene that specifies cell fates during C. elegans vulval induction, encodes a ras protein. Cell 1990, 63:921-931. 10.1016/0092-8674(90)90495-Z, 2257629.
41. Fischer A, Hekman M, Kuhlmann J, Rubio I, Wiese S, Rapp UR. B- and C-RAF display essential differences in their binding to Ras: the isotype-specific N terminus of B-RAF facilitates Ras binding. J Biol Chem 2007, 282:26503-26516. 10.1074/jbc.M607458200, 17635919.
42. Vojtek AB, Hollenberg SM, Cooper JA. Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell 1993, 74:205-214. 10.1016/0092-8674(93)90307-C, 8334704.
43. Williams JG, Drugan JK, Yi GS, Clark GJ, Der CJ, Campbell SL. Elucidation of binding determinants and functional consequences of Ras/Raf-cysteine-rich domain interactions. J Biol Chem 2000, 275:22172-22179. 10.1074/jbc.M000397200, 10777480.
44. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 2000, 351(Pt 2):289-305. 10.1042/0264-6021:3510289, 1221363, 11023813.
45. Wellbrock C, Ogilvie L, Hedley D, Karasarides M, Martin J, Niculescu-Duvaz D, Springer CJ, Marais R. V599EB-RAF is an oncogene in melanocytes. Cancer Res 2004, 64:2338-2342. 10.1158/0008-5472.CAN-03-3433, 15059882.
46. Trakul N, Menard RE, Schade GR, Qian Z, Rosner MR. Raf kinase inhibitory protein regulates Raf-1 but not B-Raf kinase activation. J Biol Chem 2005, 280:24931-24940. 10.1074/jbc.M413929200, 15886202.
47. Marais R, Light Y, Paterson HF, Mason CS, Marshall CJ. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem 1997, 272:4378-4383. 10.1074/jbc.272.7.4378, 9020159.
48. Rajakulendran T, Sahmi M, Lefrancois M, Sicheri F, Therrien M. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 2009, 461:542-545. 10.1038/nature08314, 19727074.
49. Kolch W. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol 2005, 6:827-837. 10.1038/nrm1743, 16227978.
50. Sieburth DS, Sun Q, Han M. SUR-8, a conserved Ras-binding protein with leucine-rich repeats, positively regulates Ras-mediated signaling in C. elegans. Cell 1998, 94:119-130. 10.1016/S0092-8674(00)81227-1, 9674433.
51. Selfors LM, Schutzman JL, Borland CZ, Stern MJ. soc-2 encodes a leucine-rich repeat protein implicated in fibroblast growth factor receptor signaling. Proc Natl Acad Sci USA 1998, 95:6903-6908. 10.1073/pnas.95.12.6903, 22679, 9618511.
52. Li W, Han M, Guan KL. The leucine-rich repeat protein SUR-8 enhances MAP kinase activation and forms a complex with Ras and Raf. Genes Dev 2000, 14:895-900. 316541, 10783161.
53. Herrmann C, Martin GA, Wittinghofer A. Quantitative analysis of the complex between p21ras and the Ras-binding domain of the human Raf-1 protein kinase. J Biol Chem 1995, 270:2901-2905. 10.1074/jbc.270.7.2901, 7852367.
54. Spaargaren M, Bischoff JR. Identification of the guanine nucleotide dissociation stimulator for Ral as a putative effector molecule of R-ras, H-ras, K-ras, and Rap. Proc Natl Acad Sci USA 1994, 91:12609-12613. 10.1073/pnas.91.26.12609, 45488, 7809086.
55. Wolthuis RM, Bauer B, van't Veer LJ, de Vries-Smits AM, Cool RH, Spaargaren M, Wittinghofer A, Burgering BM, Bos JL. RalGDS-like factor (Rlf) is a novel Ras and Rap 1A-associating protein. Oncogene 1996, 13:353-362.
56. Esser D, Bauer B, Wolthuis RM, Wittinghofer A, Cool RH, Bayer P. Structure determination of the Ras-binding domain of the Ral-specific guanine nucleotide exchange factor Rlf. Biochemistry 1998, 37:13453-13462. 10.1021/bi9811664, 9753431.
57. Brenner S. The genetics of Caenorhabditis elegans. Genetics 1974, 77:71-94. 1213120, 4366476.
58. Horvitz HR, Brenner S, Hodgkin J, Herman RK. A uniform genetic nomenclature for the nematode Caenorhabditis elegans. Mol Gen Genet 1979, 175:129-133. 10.1007/BF00425528, 292825.
59. Smith DB, Johnson KS. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene 1988, 67:31-40. 10.1016/0378-1119(88)90005-4, 3047011.